celecoxib has been researched along with Chronic Illness in 38 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effectiveness of celecoxib in reducing symptoms in patients with difficult chronic pelvic pain syndrome (CPPS), NIH category IIIA." | 9.14 | Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). ( Ding, GQ; Li, GH; Li, XD; Rui, XF; Yu, D; Zhang, ZG; Zhao, WP, 2009) |
| " In this double-masked, placebo-controlled, randomized clinical trial, the efficacy of celecoxib (COX-2 inhibitor) was evaluated in conjunction with scaling and root planing (SRP) in subjects with chronic periodontitis (CP)." | 9.13 | The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. ( Damoulis, PD; Hibberd, PL; Papas, AS; Singh, M; Stark, PC; Yen, CA, 2008) |
| "To evaluate the efficacy and safety of celecoxib in treating inflammatory(Type IIIA) chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS-IIIA type)." | 9.11 | [Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis]. ( Liu, J; Yang, W; Ye, Z; Zeng, X; Zhang, X; Zhou, S; Zhou, X, 2004) |
| "SD rats were randomly divided into normal control group (A), hypoxic hypercapnic group (B), hypoxic hypercapnia+ celecoxib group (C)." | 7.77 | [Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats]. ( Huang, YP; Liu, LJ; Wang, LX; Xie, YP; Zeng, HH, 2011) |
| " This study was undertaken to apply the diffusion of innovations theory to the prescribing of celecoxib and to determine if prescriber and patient characteristics differed amongst early use of celecoxib for acute pain versus chronic musculoskeletal conditions." | 7.74 | Use of celecoxib immediately post marketing in Canada: acute or chronic pain? ( Kozyrskyj, AL; Racher, A; Raymond, C, 2007) |
| "Celecoxib was used in eight patients with chronic synovitis, three patients with pain, and in one patient with a target joint on three occasions." | 5.33 | Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. ( Nugent, DJ; Rattray, B; Young, G, 2006) |
| "We investigated the effectiveness of celecoxib in reducing symptoms in patients with difficult chronic pelvic pain syndrome (CPPS), NIH category IIIA." | 5.14 | Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). ( Ding, GQ; Li, GH; Li, XD; Rui, XF; Yu, D; Zhang, ZG; Zhao, WP, 2009) |
| " In this double-masked, placebo-controlled, randomized clinical trial, the efficacy of celecoxib (COX-2 inhibitor) was evaluated in conjunction with scaling and root planing (SRP) in subjects with chronic periodontitis (CP)." | 5.13 | The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. ( Damoulis, PD; Hibberd, PL; Papas, AS; Singh, M; Stark, PC; Yen, CA, 2008) |
| "To evaluate the efficacy and safety of celecoxib in treating inflammatory(Type IIIA) chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS-IIIA type)." | 5.11 | [Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis]. ( Liu, J; Yang, W; Ye, Z; Zeng, X; Zhang, X; Zhou, S; Zhou, X, 2004) |
| "We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions." | 4.95 | Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017) |
| "SD rats were randomly divided into normal control group (A), hypoxic hypercapnic group (B), hypoxic hypercapnia+ celecoxib group (C)." | 3.77 | [Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats]. ( Huang, YP; Liu, LJ; Wang, LX; Xie, YP; Zeng, HH, 2011) |
| "Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model." | 3.74 | 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008) |
| " This study was undertaken to apply the diffusion of innovations theory to the prescribing of celecoxib and to determine if prescriber and patient characteristics differed amongst early use of celecoxib for acute pain versus chronic musculoskeletal conditions." | 3.74 | Use of celecoxib immediately post marketing in Canada: acute or chronic pain? ( Kozyrskyj, AL; Racher, A; Raymond, C, 2007) |
| " In the present study we have compared the expression profile of COX-2 protein, prostaglandin E2 (PGE2) levels and myeloperoxidase activity in acetic acid induced chronic gastric ulcer model in rats treated with omeprazole, misoprostol and COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) celecoxib." | 3.73 | Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing. ( Gautam, P; Poonam, D; Vinay, CS, 2005) |
| " Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic." | 2.82 | Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. ( Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022) |
| "Celecoxib is a cyclooxygenase-2-specific inhibitor indicated to treat acute pain and pain secondary to osteoarthritis and rheumatoid arthritis." | 2.82 | Celecoxib Versus Placebo in Tonsillectomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial. ( Bodeker, KL; Trask, DK; Van Daele, DJ, 2016) |
| "Approximately 10% of patients with plantar fasciitis have development of persistent and often disabling symptoms." | 2.71 | Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study. ( Baumhauer, JF; DiGiovanni, BF; Lintal, ME; Moore, EA; Murray, JC; Nawoczenski, DA; Wilding, GE, 2003) |
| "Celecoxib and naproxen were well tolerated, with similar number of reported adverse effects." | 2.71 | Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. ( Dionne, RA; Ta, LE, 2004) |
| "Celecoxib was used in eight patients with chronic synovitis, three patients with pain, and in one patient with a target joint on three occasions." | 1.33 | Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. ( Nugent, DJ; Rattray, B; Young, G, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (63.16) | 29.6817 |
| 2010's | 12 (31.58) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Franklin, PX | 1 |
| Pillai, AD | 1 |
| Rathod, PD | 1 |
| Yerande, S | 1 |
| Nivsarkar, M | 1 |
| Padh, H | 1 |
| Vasu, KK | 1 |
| Sudarsanam, V | 1 |
| Szabó, G | 1 |
| Fischer, J | 1 |
| Kis-Varga, A | 1 |
| Gyires, K | 1 |
| Aydogdu, O | 1 |
| Perez, F | 1 |
| Aronsson, P | 1 |
| Uyar Gocun, P | 1 |
| Carlsson, T | 1 |
| Sandner, P | 1 |
| Patel, B | 1 |
| Winder, M | 1 |
| Ziesenitz, VC | 1 |
| Welzel, T | 1 |
| van Dyk, M | 1 |
| Saur, P | 1 |
| Gorenflo, M | 1 |
| van den Anker, JN | 1 |
| Eccleston, C | 1 |
| Cooper, TE | 1 |
| Fisher, E | 1 |
| Anderson, B | 1 |
| Wilkinson, NM | 1 |
| Zhao, C | 1 |
| Li, Z | 1 |
| Ji, L | 1 |
| Ma, J | 1 |
| Ge, RL | 1 |
| Cui, S | 1 |
| Asay, JL | 1 |
| Boyer, KA | 1 |
| Andriacchi, TP | 1 |
| Caimmi, SM | 1 |
| Manca, E | 1 |
| Caimmi, D | 1 |
| Marseglia, GL | 1 |
| Demoly, P | 1 |
| Van Daele, DJ | 1 |
| Bodeker, KL | 1 |
| Trask, DK | 1 |
| Colby, JK | 1 |
| Klein, RD | 1 |
| McArthur, MJ | 1 |
| Conti, CJ | 1 |
| Kiguchi, K | 1 |
| Kawamoto, T | 1 |
| Riggs, PK | 1 |
| Pavone, AI | 1 |
| Sawicki, J | 1 |
| Fischer, SM | 1 |
| Zhao, WP | 1 |
| Zhang, ZG | 1 |
| Li, XD | 1 |
| Yu, D | 1 |
| Rui, XF | 1 |
| Li, GH | 1 |
| Ding, GQ | 1 |
| Romanò, CL | 1 |
| Romanò, D | 1 |
| Bonora, C | 1 |
| Mineo, G | 1 |
| Clarke, H | 1 |
| Kay, J | 1 |
| Mitsakakis, N | 1 |
| Katz, J | 1 |
| Bombardier, C | 2 |
| Evans, CJ | 1 |
| Katz, N | 2 |
| Mardekian, J | 1 |
| Zlateva, G | 1 |
| Simon, LS | 2 |
| Mohy El-Din, MM | 1 |
| Senbel, AM | 1 |
| Bistawroos, AA | 1 |
| El-Mallah, A | 1 |
| Nour El-Din, NA | 1 |
| Bekhit, AA | 1 |
| Abd El Razik, HA | 1 |
| Pettersen, FO | 1 |
| Torheim, EA | 1 |
| Dahm, AE | 1 |
| Aaberge, IS | 1 |
| Lind, A | 1 |
| Holm, M | 1 |
| Aandahl, EM | 1 |
| Sandset, PM | 1 |
| Taskén, K | 1 |
| Kvale, D | 1 |
| Zeng, HH | 1 |
| Liu, LJ | 1 |
| Huang, YP | 1 |
| Xie, YP | 1 |
| Wang, LX | 1 |
| Morito, H | 1 |
| Ogawa, K | 1 |
| Kobayashi, N | 1 |
| Fukumoto, T | 1 |
| Asada, H | 1 |
| Wielage, R | 1 |
| Bansal, M | 1 |
| Wilson, K | 1 |
| Klein, R | 1 |
| Happich, M | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| DiGiovanni, BF | 1 |
| Nawoczenski, DA | 1 |
| Lintal, ME | 1 |
| Moore, EA | 1 |
| Murray, JC | 1 |
| Wilding, GE | 1 |
| Baumhauer, JF | 1 |
| Giles, LG | 1 |
| Muller, R | 1 |
| Zeng, X | 1 |
| Ye, Z | 1 |
| Yang, W | 1 |
| Liu, J | 1 |
| Zhang, X | 1 |
| Zhou, X | 1 |
| Zhou, S | 1 |
| Jayr, C | 1 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Ta, LE | 1 |
| Dionne, RA | 1 |
| Poonam, D | 1 |
| Vinay, CS | 1 |
| Gautam, P | 1 |
| Klasser, GD | 1 |
| Epstein, J | 1 |
| Hayakawa, T | 1 |
| Fujiwara, Y | 1 |
| Hamaguchi, M | 1 |
| Sugawa, T | 1 |
| Okuyama, M | 1 |
| Sasaki, E | 1 |
| Watanabe, T | 1 |
| Tominaga, K | 1 |
| Oshitani, N | 1 |
| Higuchi, K | 1 |
| Arakawa, T | 1 |
| Rattray, B | 1 |
| Nugent, DJ | 1 |
| Young, G | 1 |
| Iohom, G | 1 |
| Abdalla, H | 1 |
| O'Brien, J | 1 |
| Szarvas, S | 1 |
| Larney, V | 1 |
| Buckley, E | 1 |
| Butler, M | 1 |
| Shorten, GD | 1 |
| Akhondzadeh, S | 1 |
| Tabatabaee, M | 1 |
| Amini, H | 1 |
| Ahmadi Abhari, SA | 1 |
| Abbasi, SH | 1 |
| Behnam, B | 1 |
| Kozyrskyj, AL | 1 |
| Raymond, C | 1 |
| Racher, A | 1 |
| Evans, C | 1 |
| West, C | 1 |
| Robbins, J | 1 |
| Copley-Merriman, C | 1 |
| Markman, J | 1 |
| Coombs, JH | 1 |
| Yen, CA | 1 |
| Damoulis, PD | 1 |
| Stark, PC | 1 |
| Hibberd, PL | 1 |
| Singh, M | 1 |
| Papas, AS | 1 |
| Kessenich, CR | 1 |
| Berenguer, B | 1 |
| Alarcón de la Lastra, C | 1 |
| Moreno, FJ | 1 |
| Martín, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MEASURES OF GAIT AND SELF-REPORTED PAIN IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: A RANDOMIZED, SINGLE-BLIND WASHOUT, DOUBLE-BLIND TREATMENT, DOUBLE DUMMY CROSS-OVER PILOT TRIAL USING PLACEBO, OXYCODONE AND CELECOXIB (A9011030)[NCT00484718] | Phase 4 | 6 participants (Actual) | Interventional | 2008-01-17 | Terminated (stopped due to See termination reason in detailed description.) | ||
| Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy: a Randomized, Double Blind, Placebo-controlled Trial[NCT00583453] | Phase 2 | 18 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Plantar Fasciitis Treatment: Influence of the Possible Presence of Subchondral Bone Edema[NCT05925777] | 24 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | |||
| Intense Therapeutic Ultrasound for Chronic, Subcutaneous Lateral Epicondylitis Musculoskeletal Pain Reduction[NCT03255733] | 29 participants (Actual) | Interventional | 2015-07-14 | Completed | |||
| Intense Therapeutic Ultrasound for Chronic Plantar Fascia Musculoskeletal Pain Reduction[NCT03255655] | 41 participants (Actual) | Interventional | 2014-10-22 | Completed | |||
| Photobiomodulation Therapy for Plantar Fasciitis: A Single-Blind Randomized Control Trial[NCT05763381] | 100 participants (Anticipated) | Interventional | 2022-08-11 | Recruiting | |||
| Effects of Graston Assisted Soft Tissue Mobilization in Patients With Chronic Plantar Fasciitis.[NCT04993105] | 66 participants (Actual) | Interventional | 2021-03-20 | Completed | |||
| Trigger Point Dry Needling vs Trigger Point Dry Needling With Intramuscular Electrical Stimulation for the Treatment of Sub-acute and Chronic Low Back Pain in a Military Population: A Randomized Crossover Design[NCT03539588] | 30 participants (Actual) | Interventional | 2017-04-12 | Completed | |||
| Changes in Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation in Asymptomatic Subjects[NCT01469533] | 30 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: A Randomized Clinical Trial[NCT05651256] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2021-03-01 | Completed | ||
| Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial[NCT00652093] | Phase 4 | 24 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Removal of Darvocet from US market) | ||
| Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Cross-over Trial of Pregabalin vs. Diphenhydramine in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain[NCT00638443] | Phase 4 | 29 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period. (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib 200 mg Tablets | 0 |
| Placebo With Same Dosing Schedule as the Active Comparator Arm | 0 |
Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals. (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | mg (Mean) | |||
|---|---|---|---|---|
| Day 1 | Average, days 2 to 4 | Average, days 5 to 7 | Average, days 8 to 10 | |
| Celecoxib as Experimerimental Intervention | 2074 | 2245 | 2028 | 1418 |
| Placebo Control, Active Comparator | 3006 | 2934 | 3610 | 2483 |
Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily. (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | Activity score (units on a scale) (Mean) | |||
|---|---|---|---|---|
| Day 1 | Average, days 2 to 4 | Average, days 5 to 7 | Average, days 8 to 10 | |
| Celecoxib as Experimerimental Intervention | 2.8 | 3.1 | 5.4 | 7.4 |
| Placebo Control, Active Comparator | 4.5 | 4.1 | 3.7 | 5.7 |
Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily. (NCT00583453)
Timeframe: day of procedure through post-operative day 10
| Intervention | pain score (units on a scale) (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum pain, day 1 | maximum pain, averaged across days 2 to 4 | maximum pain, averaged across days 5 to 7 | maximum pain, averaged across days 8 to 10 | Average pain, day 1 | Average pain, averaged across days 2 to 4 | Average pain, averaged across days 5 to 7 | Average pain, averaged across days 8 to 10 | Pain with drinking, day 1 | Pain with drinking, averaged across days 2 to 4 | Pain with drinking, averaged across days 5 to 7 | Pain with drinking, averaged across days 8 to 10 | Activity, day 1 | |
| Celecoxib 200 mg Tablets | 5.0 | 5.1 | 4.4 | 3.6 | 6.1 | 6.2 | 6.1 | 4.9 | 5.7 | 5.4 | 4.9 | 3.9 | 2.8 |
| Placebo With Same Dosing Schedule as the Active Comparator Arm | 6.0 | 6.0 | 5.9 | 4.0 | 7.3 | 7.6 | 7.4 | 5.7 | 6.7 | 6.6 | 5.9 | 4.1 | 4.5 |
Participant reported mophine equivalent use (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | mg (Mean) | |||
|---|---|---|---|---|
| Day 1 | Average, days 2 to 4 | Average, days 5 to 7 | Average, days 8 to 10 | |
| Celecoxib as Experimerimental Intervention | 28.9 | 30.4 | 27.8 | 13.2 |
| Placebo Control, Active Comparator | 55.0 | 72.4 | 69.7 | 38.3 |
Average Percentage of Pain Change as Reported using Patient-Rated Tennis Elbow Evaluation Survey, compared to baseline. Range (± 100%) (NCT03255733)
Timeframe: 12 weeks after 1st Treatment
| Intervention | percentage of reported pain change (Mean) |
|---|---|
| Intense Therapeutic Ultrasound Treatment | -58 |
Percentage of Patients Reporting at least 25% pain reduction compared to baseline, using Universal Visual Analog Scale (VAS) Pain Score. VAS is a 10-point Pain Scale, where 0 = No Pain, 1 = Slight Pain and 10 = the Patients Worst Imaginable Pain. Scales in between represent 10% increments of Pain ( Range 1 - 10). (NCT03255733)
Timeframe: 12 weeks after 1st Treatment
| Intervention | percentage of patients with less pain (Number) |
|---|---|
| Intense Therapeutic Ultrasound Treatment | 88 |
Average Percentage of Change as Reported using Foot Function Index (FFI) pain subscale. Range (±100%). Foot Function Index pain subscale is a measure of pain and disability and activity limitation based 9 questions, each with a possible pain score of 0 - 10, where 0 indicates no pain during the described activity and 10 indicates the worst imaginable pain during a described activity. A summed total score of 0 indicates the patient had no pain for all activities. A score of 90 indicates the patient experiences the worst imaginable pain for all the described activities. The results compare the average percentage change of the FFI score at 12 weeks, compared to the average FFI score at baseline. (NCT03255655)
Timeframe: 12 weeks after 1st Treatment
| Intervention | percentage of Change (Mean) |
|---|---|
| ITU Treatment for Chronic Plantar Fasciitis | -54 |
| Sham ITU Treatment for Chronic Plantar Fasciitis | -25 |
Mean Percentage Change in Volume of Plantar Fascia Hypoechoic Lesions by Diagnostic Ultrasound Imaging compared to Baseline Volume, where volume is calculated using: (4/3)π x R1 x R2 x R3, where R = Radius of each measurement: Lesion Length (1), Width (2), Depth (3). (NCT03255655)
Timeframe: 12 Weeks after the first Treatment
| Intervention | percentage of Hypoechoic Lesion Change (Mean) |
|---|---|
| ITU Treatment for Chronic Plantar Fasciitis | -81 |
| Sham ITU Treatment for Chronic Plantar Fasciitis | 26 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals (every 30 seconds) subjects were asked what their pain level was according to the NRS. The area under the curve of present pain intensity is the total area combined for the amount of time the subject walked. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale * minutes (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 76.0 |
| Opana Then Placebo Then Darvocet | 95.7 |
| Placebo Then Opana Then Darvocet | 95.0 |
| Placebo Then Darvocet Then Opana | 86.4 |
| Darvocet Then Opana Then Placebo | 123.3 |
| Darvocet Then Placebo Then Opana | 79.6 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals subjects were asked what their pain level was according to the NRS. When the subject reached their maximum distance, they were asked their NRS score. This was recorded as final pain intensity. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 4.6 |
| Opana Then Placebo Then Darvocet | 6.6 |
| Placebo Then Opana Then Darvocet | 6.2 |
| Placebo Then Darvocet Then Opana | 6.7 |
| Darvocet Then Opana Then Placebo | 8.0 |
| Darvocet Then Placebo Then Opana | 7.1 |
The mBPI is a series of questions that rates the severity and impact of pain on daily function. The questionnaire is made up of 4 pain severity items using the NRS scale, and seven 11-point pain interference scales (0 indicating no interference and 10 indicating complete interference). For the interference score, a total score of 10 indicates pain completely interferes with activities. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 3.7 |
| Opana Then Placebo Then Darvocet | 4.2 |
| Placebo Then Opana Then Darvocet | 2.7 |
| Placebo Then Darvocet Then Opana | 4.3 |
| Darvocet Then Opana Then Placebo | 6.2 |
| Darvocet Then Placebo Then Opana | 2.8 |
The ODI is a set of 10 questions each with five choices (maximum score of 5 points per question) designed to determine how back pain has affected the ability to manage everyday life (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, social life, traveling, and change positions). A score of 0 indicates no disability and total score of 50 would indicate 100% disability. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 37.9 |
| Opana Then Placebo Then Darvocet | 98.4 |
| Placebo Then Opana Then Darvocet | 38.0 |
| Placebo Then Darvocet Then Opana | 44.1 |
| Darvocet Then Opana Then Placebo | 37.0 |
| Darvocet Then Placebo Then Opana | 29.7 |
Subjects were asked to rate their low back pain according to the PGA. PGA is the impact of disease activity. PGA was measured on a 5-point scale, where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 2.8 |
| Opana Then Placebo Then Darvocet | 2.8 |
| Placebo Then Opana Then Darvocet | 3.1 |
| Placebo Then Darvocet Then Opana | 2.6 |
| Darvocet Then Opana Then Placebo | 3.3 |
| Darvocet Then Placebo Then Opana | 2.6 |
After the subject completed the treadmill test they were asked to immediately return to the seated position. At this point a timer was started. When the subjects pain level returned to baseline (level of pain subject felt in a seated position before walking) the time was stopped. This was recorded as recovery time. Maximum recovery time is 15 minutes. (NCT00652093)
Timeframe: study visit
| Intervention | minutes (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 1.10 |
| Opana Then Placebo Then Darvocet | 1.50 |
| Placebo Then Opana Then Darvocet | 2.02 |
| Placebo Then Darvocet Then Opana | 1.58 |
| Darvocet Then Opana Then Placebo | 2.15 |
| Darvocet Then Placebo Then Opana | 1.57 |
The RMDQ consists of 24 yes/no statements about activity limitations due to back pain. These questions center on movement, ambulation, and self-care activities. Positive (yes) answers each contribute 1 point to cumulative score with total scores ranging from 0 (no disability) to 24 (severely disabled). (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 12.8 |
| Opana Then Placebo Then Darvocet | 15.3 |
| Placebo Then Opana Then Darvocet | 13.2 |
| Placebo Then Darvocet Then Opana | 15.2 |
| Darvocet Then Opana Then Placebo | 13.7 |
| Darvocet Then Placebo Then Opana | 7.4 |
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The physical function section is a series of 5 questions (maximum 4 points per question) and asks to rate function for each question based on comfortably, sometimes with pain, always with pain, no functional ability. The total score (max=20) is divided by five. The maximum score for the physical function section (max=4) indicates no ability to function. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 2.5 |
| Opana Then Placebo Then Darvocet | 2.5 |
| Placebo Then Opana Then Darvocet | 2.6 |
| Placebo Then Darvocet Then Opana | 2.6 |
| Darvocet Then Opana Then Placebo | 2.6 |
| Darvocet Then Placebo Then Opana | 2.2 |
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The symptom severity section is a set of 7 questions (maximum score is 5 points per question) and asks to rate pain for each question based on no pain, mild, moderate, severe or very severe pain. The total score (maximum=35) is added up and divided by seven. The maximum score for the symptom severity section (score=5) indicates very severe symptom severity. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 2.6 |
| Opana Then Placebo Then Darvocet | 2.9 |
| Placebo Then Opana Then Darvocet | 3.2 |
| Placebo Then Darvocet Then Opana | 3.2 |
| Darvocet Then Opana Then Placebo | 3.6 |
| Darvocet Then Placebo Then Opana | 2.9 |
Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured. Patients were excluded from the trial if there pain at rest was greater than or equal to 4/10. (NCT00652093)
Timeframe: study visit
| Intervention | minutes (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 1.73 |
| Opana Then Placebo Then Darvocet | 3.02 |
| Placebo Then Opana Then Darvocet | 3.93 |
| Placebo Then Darvocet Then Opana | 2.65 |
| Darvocet Then Opana Then Placebo | 0.83 |
| Darvocet Then Placebo Then Opana | 5.43 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. When the subject reached their maximum distance, the treadmill testing was stopped. This was recorded as total distance based on number of minutes and seconds walked. Minutes was converted to meters based on calculation of defined speed of the treadmill. (NCT00652093)
Timeframe: study visit
| Intervention | meters (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 266.6 |
| Opana Then Placebo Then Darvocet | 249.5 |
| Placebo Then Opana Then Darvocet | 177.9 |
| Placebo Then Darvocet Then Opana | 290.1 |
| Darvocet Then Opana Then Placebo | 160.8 |
| Darvocet Then Placebo Then Opana | 294.8 |
The VAS asked subjects to place a mark indicative of their low back pain during the past day on a 100mm line, with 0mm representing no pain and 100mm representing extreme pain. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 51.3 |
| Opana Then Placebo Then Darvocet | 57.9 |
| Placebo Then Opana Then Darvocet | 56.2 |
| Placebo Then Darvocet Then Opana | 46.7 |
| Darvocet Then Opana Then Placebo | 63.3 |
| Darvocet Then Placebo Then Opana | 55.1 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals (every 30 seconds) subjects were asked what their pain level was according to the NRS. The area under the curve of present pain intensity multiplied by the amount of time the subject walked. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale * minutes (Mean) |
|---|---|
| Pregabalin | 100.59 |
| Diphenhydramine | 95.26 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals subjects were asked what their pain level was according to the NRS. When the subject reached their maximum distance, they were asked their NRS score. This was recorded as final pain intensity. Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 1.82 |
| Diphenhydramine | 1.53 |
The mBPI is a series of questions that rates the severity and impact of pain on daily function. The questionnaire is made up of 4 pain severity items using the NRS scale, and seven pain interference sub-scales. The final interference score is an average of the seven sub-scales (0 indicating no interference and 10 indicating complete interference). (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 3.70 |
| Diphenhydramine | 3.58 |
The ODI is a set of 10 questions each with five choices (maximum score of 5 points per question) designed to determine how back pain has affected the ability to manage everyday life (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, social life, traveling, and change positions). A total score range of 0-50; score of 0 indicates no disability and a score of 50 would indicate 100% disability. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 37.77 |
| Diphenhydramine | 36.49 |
Subjects were asked to rate their low back pain according to the PGA. PGA is the impact of disease activity. PGA was measured on a 5-point scale, where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 2.75 |
| Diphenhydramine | 2.83 |
After the subject completed the treadmill test they were asked to immediately return to the seated position. At this point a timer was started. When the subjects pain level returned to baseline (level of pain subject felt in a seated position before walking) the time was stopped. This was recorded as recovery time. Maximum recovery time is 15 minutes. (NCT00638443)
Timeframe: 10 days
| Intervention | minutes (Mean) |
|---|---|
| Pregabalin | 2.36 |
| Diphenhydramine | 3.15 |
The RMDQ consists of 24 yes/no statements about activity limitations due to back pain. These questions center on movement, ambulation, and self-care activities. Positive (yes) answers each contribute 1 point to cumulative score with total scores ranging from 0 (no disability) to 24 (severely disabled). (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 12.98 |
| Diphenhydramine | 11.48 |
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The symptom severity section is a set of 7 questions (maximum score is 5 points per question) and asks to rate pain for each question based on no pain, mild, moderate, severe or very severe pain. The total score (maximum=35) is added up and divided by seven. The maximum score for the symptom severity section (score=5) indicates very severe symptom severity. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 3.09 |
| Diphenhydramine | 2.94 |
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The physical function section is a series of 5 questions (maximum 4 points per question) and asks to rate function for each question based on comfortably, sometimes with pain, always with pain, no functional ability. The total score (max=20) is divided by five. The maximum score for the physical function section (max=4) indicates no ability to function. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 2.40 |
| Diphenhydramine | 2.94 |
Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured. (NCT00638443)
Timeframe: 10 days
| Intervention | minutes (Mean) |
|---|---|
| Pregabalin | 2.52 |
| Diphenhydramine | 3.06 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. When the subject reached their maximum distance, the treadmill testing was stopped. This was recorded as total distance based on number of minutes and seconds walked. Minutes was converted to meters based on calculation of defined speed of the treadmill. (NCT00638443)
Timeframe: 10 days
| Intervention | meters (Mean) |
|---|---|
| Pregabalin | 237.49 |
| Diphenhydramine | 261.55 |
The VAS asked subjects to place a mark indicative of their low back pain during the past day on a 100mm line, with 0mm representing no pain and 100mm representing extreme pain. (NCT00638443)
Timeframe: 10 days
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 52.31 |
| Diphenhydramine | 46.31 |
7 reviews available for celecoxib and Chronic Illness
| Article | Year |
|---|---|
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; C | 2022 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp | 2017 |
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; C | 2013 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr | 2001 |
14 trials available for celecoxib and Chronic Illness
| Article | Year |
|---|---|
Repeatability of gait analysis for measuring knee osteoarthritis pain in patients with severe chronic pain.
Topics: Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Biomechanical Phenome | 2013 |
Celecoxib Versus Placebo in Tonsillectomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Celecoxib; Chronic Disease; Cycl | 2016 |
Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA).
Topics: Adolescent; Adult; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Humans; Male; Middle Age | 2009 |
Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain.
Topics: Adult; Aged; Analgesics; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Drug Therapy, Comb | 2009 |
Acute pain after total hip arthroplasty does not predict the development of chronic postsurgical pain 6 months later.
Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Aged; Arthroplasty, Replacement, Hip; Celecoxib; Ch | 2010 |
An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.
Topics: Adult; AIDS Vaccines; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Disease Progression; | 2011 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Tissue-specific plantar fascia-stretching exercise enhances outcomes in patients with chronic heel pain. A prospective, randomized study.
Topics: Achilles Tendon; Activities of Daily Living; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecox | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
[Clinical evaluation of celecoxib in treating type IIIA chronic prostatitis].
Topics: Adult; Celecoxib; Chronic Disease; Cyclooxygenase Inhibitors; Humans; Male; Middle Aged; Prostatitis | 2004 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
Topics: Adult; Celecoxib; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2004 |
The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
Topics: Acetaminophen; Adult; Aged; Analgesia; Anxiety; Breast Neoplasms; Bupivacaine; Celecoxib; Chronic Di | 2006 |
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Basal Ganglia Diseases; Celeco | 2007 |
The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Combin | 2008 |
17 other studies available for celecoxib and Chronic Illness
| Article | Year |
|---|---|
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib | 2008 |
New celecoxib derivatives as anti-inflammatory agents.
Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cy | 2008 |
Treatment with the soluble guanylate cyclase activator BAY 60-2770 normalizes bladder function in an in vivo rat model of chronic prostatitis.
Topics: Animals; Benzoates; Biphenyl Compounds; Celecoxib; Chronic Disease; Cystitis; Guanylate Cyclase; Hum | 2022 |
PI3K-Akt Signal Transduction Molecules Maybe Involved in Downregulation of Erythroblasts Apoptosis and Perifosine Increased Its Apoptosis in Chronic Mountain Sickness.
Topics: Adult; Altitude Sickness; Apoptosis; bcl-X Protein; Bone Marrow Cells; Caspase 9; Celecoxib; China; | 2017 |
NSAID hypersensitivity in twins.
Topics: Adolescent; Allergens; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Celecoxib; Child; Ch | 2014 |
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Transformation, Neoplastic | 2008 |
Further qualification of a therapeutic responder index for patients with chronic low back pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Celecoxib; Chronic Disease; Cyclooxy | 2011 |
A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Celecoxib; Chronic | 2011 |
[Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats].
Topics: Animals; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Epoprostenol; Hypercapnia; Hyperte | 2011 |
Drug-induced hypersensitivity syndrome followed by persistent arthritis.
Topics: Anti-Arrhythmia Agents; Arthralgia; Arthritis; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibito | 2012 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.
Topics: Animals; Anti-Ulcer Agents; Blotting, Western; Celecoxib; Chronic Disease; Cyclooxygenase 2; Dinopro | 2005 |
Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis.
Topics: Animals; Celecoxib; Cell Division; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygena | 2006 |
Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Celecoxib; Child; Chronic Di | 2006 |
Use of celecoxib immediately post marketing in Canada: acute or chronic pain?
Topics: Acute Disease; Adult; Aged; Canada; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Diffusi | 2007 |
Preliminary development of a responder index for chronic low back pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic | 2007 |
Preliminary development of a responder index for chronic low back pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic | 2007 |
Preliminary development of a responder index for chronic low back pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic | 2007 |
Preliminary development of a responder index for chronic low back pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic | 2007 |
Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; | 2002 |